Resistin gene promoter region polymorphism and the risk of hypertrophic cardiomyopathy in patients

Translational Research

Volumn 155, Issue 3, 2010, Pages 142-147

  Hussain, Sabir ^a   Asghar, Muhammad ^b   Javed, Qamar ^a  

^a QUAID I AZAM UNIVERSITY   (Pakistan)

^b Siddique Sadiq Memorial Trust Cardiac Institute   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

RESISTIN;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 76549130485     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.10.002     Document Type: Article

References (24)

1. Spirito P., Seidman C.E., McKenna W.J., and Maron B.J. The management of hypertrophic cardiomyopathy. N Engl J Med 336 (1997) 775-785
2. Wolf C.M., Moskqwitz I.P., Arno S., et al. Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc Natl Acad Sci U S A 102 (2005) 18123-18128
3. Kofflard M.J., Ten Cate F.J., Van der Lee C., and van Domburg R.T. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 41 (2003) 987-993
4. Hoffmann B., Schmidt-Traub H., Perrot A., Osterziel K.J., and Gessner R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum Mutat 17 (2001) 524
5. Olson T.M., Karst M.L., Whitby F.G., and Driscoll D.J. Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation 105 (2002) 2337-2340
6. Niimura H., Bachinski L.L., Sangwatanaroj S., et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 338 (1998) 1248-1257
7. Hayashi T., Arimura T., Itoh-Satoh M., et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 44 (2004) 2192-2201
8. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
9. Patel L., Buckels A.C., Kinghorn I.J., et al. Resistin is expressed in human macrophages and directly by PPAR gamma activators. Biochem Biophys Commun 300 (2003) 472-476
10. Qiao X.Z., Yang Y.M., Xu Z.R., and Yang L.A. Relationship between resistin level in serum and acute coronary syndrome or stable angina pectoris. J Zhejiang Univ Sci B 8 (2007) 875-880
11. Cho Y.M., Youn B.S., Chung S.S., et al. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentration in humans. Diabetologia 47 (2004) 559-565
12. Azuma K., Oguchi S., Matsubara Y., et al. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res 36 (2004) 564-570
13. Osawa H., Yamada K., Onuma H., et al. The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 75 (2004) 678-686
14. Tang N.P., Wang L.S., Yang L., et al. A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population. Clin Endocrinol 68 (2008) 82-87
15. Kunnari A., Ukkola O., and Kesäniemi Y.A. Resistin polymorphisms are associated with cerebrovascular disease in Finnish Type 2 diabetic patients. Diabet Med 22 (2005) 583-589
16. Kim M., Oh J.K., Sakata S., et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 45 (2008) 270-280
17. McKenna W.J., Spirito P., Desnos M., Dubourg O., and Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 77 (1997) 130-132
18. Hall T.A. BioEdit: a user friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucli Acid Symp (1999) 4195-4198
19. Tsukahara T., Nakashima E., Watarai A., et al. Polymorphism in resistin promoter region at-420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 84 (2009) 179-186
20. Chu S., Ding W., Li K., Pang Y., and Tang C. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 72 (2008) 1249-1253
21. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
22. Weikert C., Westphal S., Berger K., et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 93 (2008) 2647-2653
23. Takeishi Y., Niizeki T., Arimoto T., et al. Serum resistin is associated with high risk in patients with congestive heart failure-a novel link between metabolic signals and heart failure. Circ J 71 (2007) 460-464
24. Osawa H., Onuma H., Ochi M., et al. Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun 335 (2005) 596-602